α‑KG scarcity skews bivalent domain resolution in aging versus cancer through opposing KDM5/KDM6 activity
Hypothesis
Age‑dependent decline in glutamine import reduces intracellular α‑KG, selectively inhibiting KDM6 demethylases and causing H3K27me3 accumulation at bivalent promoters of tumor‑suppressor genes. Cancer cells overcome this block by upregulating SLC1A5‑mediated glutamine uptake and overexpressing KDM5A, which removes H3K4me3 marks and shifts the same loci toward an active chromatin state, thereby locking in oncogenic transcription.
Mechanistic Basis
- In aging tissues, reduced SLC1A5 expression lowers glutamine flux, limiting α‑KG availability for the Fe²⁺/α‑KG‑dependent KDM6 family (KDM6A/B)【1】. This creates a biochemical bias where KDM6 activity falls faster than KDM5 activity, tipping the H3K4me3/H3K27me3 balance at bivalent domains toward repression.
- Cancer cells frequently exhibit glutamine addiction and heightened SLC1A5 expression, sustaining α‑KG levels that preserve KDM6 function. Simultaneously, oncogenic signaling (e.g., PI3K/AKT) drives KDM5A overexpression【2】, increasing H3K4me3 demethylation and facilitating R‑loop‑mediated viral mimicry when inhibited【4】.
- The opposing enzymatic trajectories at identical genomic loci could explain why aged tissues show a senescence‑associated H3K27me3‑rich landscape, whereas tumors display H3K4me3‑enriched promoters at the same genes, a dichotomy not yet captured by existing cancer‑or‑aging studies.
Testable Predictions
- Metabolite‑enzyme correlation: In matched young, aged, and tumor samples from the same tissue type, α‑KG concentration will inversely correlate with H3K27me3 levels at bivalent promoters and positively correlate with KDM6 activity, while KDM5A protein levels will inversely correlate with H3K4me3 at those loci.
- Genetic rescue: Restoring SLC1A5 expression in aged tissue will increase α‑KG, enhance KDM6‑mediated H3K27me3 removal, and reduce senescence markers without altering KDM5A levels.
- Oncogenic reversal: Knocking down KDM5A in cancer cells with high glutamine flux will decrease H3K4me3 at bivalent promoters, increase H3K27me3, and sensitize tumors to interferon‑based immunotherapy via restored viral mimicry.
- Pharmacological modulation: Treating aged organoids with cell‑permeable α‑KG esters will mimic the cancer‑like shift toward H3K4me3 dominance at tumor‑suppressor loci, whereas treating cancer organoids with a KDM5 inhibitor will restore H3K27me3 and reduce proliferation.
Experimental Approach
- Sample collection: Obtain fresh‑frozen young (3 mo), aged (24 mo), and syngeneic tumor tissues from mouse models of liver, lung, and breast; process parallel human specimens where available.
- Metabolite profiling: Quantify glutamine, glutamate, and α‑KG using LC‑MS/MS.
- Chromatin mapping: Perform CUT&Tag for H3K4me3, H3K27me3, and KDM5A/KDM6B occupancy; focus on promoters defined as bivalent in embryonic stem cells (e.g., Cdkn2a, p53 pathway genes).
- Activity assays: Measure in‑vitro demethylase activity from nuclear extracts normalized to α‑KG levels.
- Functional validation: Use AAV‑mediated SLC1A5 overexpression in aged mice; CRISPRi KD of KDM5A in tumor cells; assess senescence (SA‑β‑gal), apoptosis, and tumor growth.
- Immunotherapy test: Combine KDM5A inhibition with anti‑PD‑1 in tumor‑bearing mice and monitor survival and IFN‑stimulated gene signatures.
Expected Outcomes
If the hypothesis holds, aged tissues will show low α‑KG, high H3K27me3, and low KDM6 activity at bivalent tumor‑suppressor promoters, while tumors will display high α‑KG, elevated KDM5A, high H3K4me3, and low H3K27me3 at the same sites. Manipulating glutamine flux or KDM5 activity should flip these epigenetic states in predictable directions, directly linking metabolic aging mechanisms to cancer epigenetics.
Implications
Demonstrating a shared metabolic‑epigenetic axis would reframe aging‑associated epigenetic drift not as random noise but as a reversible block that cancers exploit. It would also suggest that dietary or pharmacological modulation of glutamine metabolism could simultaneously mitigate age‑related dysfunction and prevent epigenetic reprogramming toward malignancy.